Data from EMC - Curated by Toby Galbraith - Last updated 17 March 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

More information

Category Value
Agency product number EMEA/H/C/002826
Orphan designation Yes
Date First Approved 03-03-2017
Type POM
Marketing authorisation holder Actelion Registration Ltd.

Related Content